Adrenomed AG, the vascular integrity company, today announced the closing of a €24 million series D financing round. The new funds will be invested in the clinical development program of lead product candidate Adrecizumab. Adrecizunab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM).
by eazee-designstudio
The recently completed Phase 2 clinical trial was designed to assess the safety, tolerability and immunogenicity of its lead vaccine candidate (MV-CHIK) to protect against Chikungunya fever, a mosquito-transmitted disease that has no current treatment or prevention options. The primary endpoint, defined as the presence of neutralizing antibodies against Chikungunya, four weeks after administration of one or two MV-CHIK injections, was met across all treatment groups.
Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry.
German diagnostics company sphingotec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners. Sphingotec will primarily use the proceeds to roll out the fully automated IB 10 point-of-care (POC) platform for testing of a broad panel of acute blood biomarkers, which had been acquired in May 2018 through an acquisition of Samsung-subsidiary Nexus Dx Inc.
Themis announced positive interim results from an ongoing phase 2 clinical study designed to demonstrate safety and immunogenicity of MV-CHIK, its live attenuated prophylactic vaccine candidate for chikungunya fever. The data will be presented for the first time at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Baltimore, MA, USA.
Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a $53 million Series A financing to further expand its CAR-Macrophage platform – the first technology to combine antigen recognition with the effector function of macrophages – and to rapidly drive its programs toward clinical development.
TRiCares today announced the successful completion of a €22 million Series B financing round to fund the development of minimally invasive treatment of tricuspid regurgitation. Proceeds from the financing will be used to advance product development, to conduct clinical trials and to gain CE registration in Europe.
4SC AG today announced that Yakult Honsha Co. Ltd., 4SC’s development partner for resminostat in Japan, opens additional clinical centers in Japan and contributes patients to the RESMAIN study. Additionally, 4SC received a milestone payment.
Today Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. The investment of up to $37,500,000 represents an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak.
Themis has established a Scientific Advisory Board (SAB) with the appointment of Christian W. Mandl, Ph.D., MD, W. Paul Duprex, Ph.D., Stephen J. Thomas, MD and Nadia G. Tornieporth, MD. The newly-formed SAB brings a wealth of experience in molecular virology, viral pathogenesis and vaccine development. The purpose of the SAB will be to advise Themis as it continues to develop its pipeline of urgently needed vaccines and immune system activation approaches.
